Skip to main content
NC3Rs: National Centre for the Replacement Refinement & Reduction of Animals in Research
In-person

Navigating the NAM pathway: From innovation to implementation

-

Registration Details

Event date and time
-
Organiser
NC3Rs
Location
Central London
This event has reached capacity.

If you would like to join the waitlist, complete the registration form and we will be in touch by 15 June to confirm whether your registration has been approved.

Be the first to know about future events in this area by registering for the NC3Rs NAMs Network.

This NC3Rs NAMs Network event will focus on how new approach methodologies (NAMs)* can move from scientific innovation into real-world use in industry and regulatory decision making to replace the use of animals in safety testing. 

The meeting will bring together method developers, regulators, industry, contract research organisations and policy stakeholders to explore the practical steps needed to accelerate uptake and implementation of NAMs across sectors. There will be a particular focus on capability building for method developers and progressing NAMs towards industry use and regulatory acceptance, recognising differences across sectors and regulatory regimes.

Agenda

The meeting will be chaired by Camilla Alexander-White, MKTox Consultancy and chair of the NC3Rs Regulatory Sciences Forum.

There will be opportunities for poster viewing and networking throughout the day.

Welcome and registration

TimeSession
10.00 – 10.30Registration
10.30 – 10.45

Introduction and welcome 

Dr Camilla Alexander-White, MKTox & Co (Chair)
Dr Amy Marriott, NC3Rs

10.45 – 11.00

Overview of the UK Government Strategy on Replacing Animals in Science

Dr Anthony Holmes, NC3Rs/Office for Life Sciences

Session one: Building partnerships and facilitating industry uptake

TimeSession
11.00 – 11.20

Review of the UK preclinical model landscape and ensuring translational readiness

Dr Catherine Vickers, NC3Rs

11.20 – 11.35

Overview of Innovate UK Business Connect: Connecting innovators with new partners and opportunities navigate the innovation pipeline

Dr Jessica Dobson, Innovate UK

11.35 – 11.50

Highlights from the NAMs Network In Conversation webinar: Overcoming barriers to commercialisation

Dr Helen Maddock, InoCardia Ltd
Dr Marjolein Wildwater, Vivaltes
Dr Victoria Hutter, ImmuONE

11.50 – 12.40

Quick-fire overviews from awardees of the NC3Rs/BBSRC Business Interaction Scheme on their partnerships to progress method uptake

Dr Jessica Ewald, European Molecular Biology Laboratory
Professor Felicity Gavins, Brunel University of London
Dr Julia Mantaj, London South Bank University
Dr Ben Mellows, University of Oxford
Dr Katarzyna Pirog, Newcastle University

12.40 – 13.00Panel discussion: The importance of partnerships

Session two: Progressing towards regulatory acceptance

TimeSession
14.00 – 14.10

Overview of OECD test method standardisation and adoption processes

TBC, UK Department for Environment, Food and Rural Affairs (Defra)

14.10 – 14.30

Progress in the standardisation and validation of new or updated test methods for hazard assessment, including complex measurement technologies

Dr Julia Malinowska, European Commission Joint Research Centre

14.30 – 14.50

Overview of the European Commission Roadmap towards phasing out animal testing for chemical safety assessments

Dr Georg Streck, European Commission (virtual) 

14.50 – 15.10

MHRA: Regulation and reducing animal use in drug development

Dr James McBlane, Medicines and Healthcare products Regulatory Agency (MHRA)

15.10 – 15.30

Contract Research Organisation perspective on validation and qualification

Dr Mary McElroy, Charles River Laboratories

 Session three: NAMs in action

TimeSession
15.50 – 16.10

NAM-based frameworks for assessing endocrine activity in aquatic vertebrates: Data driven case studies to support next steps

Dr Julie Krzykwa, Health and Environmental Sciences Institute (HESI)

16.10 – 16.30

A case study with benzoic acid demonstrating how integration of in silico tools, mechanistic in vitro NAM, and toxicological data improves definition of point of departure for a chemically defined class in read-across assessments

Dr Cathy Lester, Procter & Gamble (virtual)
Dr Camilla Alexander-White, MKTox&Co

16.30 – 16.50

The devTOX quickPredict™ assay: A highly reproducible in vitro NAM for developmental toxicity prediction and early decision making

Dr Daniel Bramham, Labcorp

16.50 – 17.10Panel discussion
17.10 – 17.20Meeting reflections and wrap-up
17.20 – 18.00Networking reception

About the NC3Rs NAMs Network

The NC3Rs NAMs Network is a community of over 700 researchers, developers, industry end-users and regulators working to accelerate the use of new approach methodologies – replacement technologies for use in toxicology and safety assessment. Network events promote dialogue and information exchange between members, supporting the formation of new collaborations and sharing technologies and experience to maximise their scientific and 3Rs impact. We encourage stakeholders from across the NAMs sector to join the Network, where amongst other benefits you will receive early notification of relevant events and initiatives.

Learn more about Network activities, explore the benefits of becoming a member and sign up to the NC3Rs NAMs Network.

Registration information

Registration closes: Thursday 4 June.

Capacity for this event is limited and registrations will be confirmed on a first-come-first-served basis,  please register early to secure your place. To ensure an effective and engaging event for all attendees, registrations will be checked for relevance to the NC3Rs NAMs Network remit. You do not need to be a Network member to register, but please note that this meeting is specifically for method developers, regulators, industry, contract research organisations and policy stakeholders with expertise in developing, validating and implementing new approach methodologies* in toxicology and regulatory sciences.

Please register for the event using an institutional email address. Registrations will be reviewed in line with our terms and conditions and policy on attendance at NC3Rs events (PDF).


* We use the term new approach methodologies specifically to refer to full and partial replacement approaches for assessing chemical or drug toxicity. Learn more about NAMs terminology